The Selux NGP System is a rapid phenotypic AST platform delivering results from positive blood culture and isolates in as little as 5.5 hours. Learn more about the power of Selux here: https://seluxdx.co/4esvoR2 . . . #AMR #AntibioticResistance #RapidAST #NGP #Superbugs #SeluxDx #AllSampleTypes
Selux Diagnostics, Inc
生物技术研究
Boston，Massachusetts 4,362 位关注者
Precision diagnostics for infectious disease.
关于我们
Selux Diagnostics is developing a Next Generation Phenotyping (NGP) platform that promises to transform infectious disease patient treatment by dramatically increasing the speed and accuracy with which targeted, personalized antibiotic therapies can be prescribed. Earlier, better-informed treatment decisions will save lives, improve patient outcomes, decrease hospital lengths of stay and hospital acquired infections, and help combat the global antibiotic resistance epidemic. The CDC has cited bacterial resistance to antibiotics among the world’s deadliest and costliest health threats. Using current technologies, doctors must overprescribe powerful, broad-spectrum antibiotics for days while waiting for key diagnostic results to direct personalized therapy. SeLux NGP is the only platform capable of delivering personalized therapy results for all patients within a day of hospital entry, speeding this targeted treatment by an average of 2 days and as many as 4 days for patients infected with multi-drug resistant organisms. Selux Diagnostics was founded in 2014 by two Yale- and Harvard-trained engineers working in an improvised attic laboratory. On September 25, 2018, SeLux announced that it had signed a milestone-based contract worth up to $45 million with BARDA, a division of the U.S. Department of Health and Human Services’ (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR). SeLux immediately receives $9.3 million from BARDA to fund the clinical trial necessary for SeLux NGP, SeLux's next-generation phenotyping platform. The additional $36 million will fund the development of SeLux's second-generation rapid sepsis diagnostic system. SeLux has also raised $25 million in Series B financing to support the pivotal FDA trial for SeLux’s NGP platform. The round was led by Sands Capital Ventures and included returning investors RA Capital and Schooner Capital and new investors Sands Capital and Northpond Ventures.
- 网站
-
https://seluxdx.com/
Selux Diagnostics, Inc的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Boston，Massachusetts
- 类型
- 私人持股
- 创立
- 2014
地点
-
主要
获取路线
56 Roland St
US，Massachusetts，Boston
Selux Diagnostics, Inc员工
动态
-
On Sunday, Selux had the pleasure of hosting Jack and Jill of America, Inc. Boston Chapter intermediate group for a day of hands-on science experiments and learning in the lab. It was an honor to share our work with these future leaders, and we can’t wait to see what they'll accomplish in the years to come. A special thank you to Rafael Francis, Nikitha Sam, and Christina Alexander for organizing and hosting this incredible event. #RapidAST #AntibioticResistance #NGP #Superbugs #SeluxDx #AllSampleTypes
-
-
Selux is celebrating 10 years of combating superbugs! We're incredibly proud of the work we've done over the last decade to launch the Selux NGP System, providing rapid AST results to patients when they need it most. #AntibioticResistance #RapidAST #NGP #Superbugs #SeluxDx #AllSampleTypes
-
-
We're spreading the word, not superbugs. Selux is at the forefront of the fight against antimicrobial resistance (AMR). Learn how the Selux NGP System delivers rapid AST results that empower clinicians to make faster, more targeted treatment decisions for better patient care: https://seluxdx.co/3YT4c8k . . . #AMR #AntibioticResistance #RapidAST #NGP #Superbugs #SeluxDx #WAAW #AntimicrobialResistance #AllSampleTypes
-
-
A presentation by Dr. Thomas Kirn, MD, Ph.D., "Does Speed Matter? The Financial and Clinical Impact of Rapid AST," highlights that shorter non-blood culture isolate AST turnaround times resulted in statistically significant reductions in length of stay (LOS), hospital costs, and pharmacy costs. What's arguably even more important, is that the odds of a patient being discharged to home increased. Learn more about how the the Selux AST System is the only FDA-cleared platform capable of performing rapid AST direct from positive blood culture AND isolates. Check out his full presentation to learn more about why performing rapid AST on isolated colonies is critical to better patient care: https://seluxdx.co/3Cr5nEe . . . #AntibioticResistance #RapidAST #NGP #Superbugs #SeluxDx #AllSampleTypes
-
-
This week is the WHO's World Antimicrobial Awareness Week. At Selux, it's our mission to preserve the lifesaving power of antibiotics for future generations. Check out how we're making an impact: https://seluxdx.co/3Cs0PgZ . . . #AntibioticResistance #RapidAST #NGP #Superbugs #SeluxDx #WAAW #AntimicrobialResistance #AllSampleTypes
-
-
Dr. Thomas Kirn, MD, Ph.D., says that speed most definitely matters when it comes to antibiotic susceptibility testing (AST), both from a cost perspective and a clinical perspective. He highlights that shorter turnaround times (TTR) on isolates lead to better patient outcomes, shorter hospital stays, and reduced costs. Learn more about how Selux's single-platform technology supports clinicians and patients by providing rapid AST results direct from positive blood culture and isolates. Watch Dr. Kirn's full presentation here: https://seluxdx.co/3UCHi3z . . . #AntibioticResistance #RapidAST #NGP #Superbugs #SeluxDx #AllSampleTypes
-
-
Did you know that the Selux AST System is the only FDA-cleared platform capable of performing rapid AST direct from positive blood culture and isolates? The single-platform technology helps boost lab efficiency by delivering results in as little as 5.5 hours, ultimately leading to faster, better patient care. Dive into the details here: https://seluxdx.co/40xqKhg . . . #AntibioticResistance #RapidAST #NGP #Superbugs #SeluxDx #AllSampleTypes
-
-
With the new data that's come out on antimicrobial resistance (AMR), it's now more important than ever to evaluate technologies tackling this global health crisis, particularly rapid antibiotic susceptibility testing (AST). Dr. Thomas Kirn, MD, Ph.D., revealed that 63% of patients had an antibiotic change after receiving rapid AST results. How does this relate to AMR? Rapid AST helps inform treatment decisions, reducing the time spent on ineffective therapies that can contribute to AMR. Learn more about how the Selux NGP System was designed to help preserve the lifesaving power of antibiotics: https://seluxdx.co/3Az0Ajt "Does Speed Matter? The Clinical and Financial Impact of Rapid AST:" https://seluxdx.co/3YwRb43 . . . #AntibioticResistance #RapidAST #NGP #Superbugs #SeluxDx #AllSampleTypes
-
-
Meet the team at Selux Diagnostics, pushing the boundaries of rapid AST technology to ensure patients receive faster, more precise treatment: https://seluxdx.co/48zFNsM . . . #AntibioticResistance #RapidAST #NGP #Superbugs #SeluxDx #AllSampleTypes
-